United States v. Saad Sakkal

Court of Appeals for the Sixth Circuit·Decided May 31, 2023·No. 20-3880·Unpublished

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 23a0242n.06

No. 20-3880

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT FILED May 31, 2023

) DEBORAH S. HUNT, Clerk UNITED STATES OF AMERICA, )

Plaintiff-Appellee, )

) ON REMAND FROM THE v. ) SUPREME COURT OF THE ) UNITED STATES

SAAD SAKKAL, M.D., )

Defendant-Appellant. ) OPINION )

Before: ROGERS, COLE, and STRANCH, Circuit Judges.

ROGERS, Circuit Judge.

With the express concurrence of the Government, the Supreme Court has vacated and remanded our affirmance of defendant Sakkal’s convictions for illegal distribution of controlled substances in violation of 21 U.S.C. § 841(a). In the previous appeal we rejected Sakkal’s arguments that he was improperly denied bail, that the evidence against him was not sufficient, and that his trial counsel was ineffective in two ways that had been addressed by the district court following a hearing. We declined to address other ineffective-assistance issues on direct appeal and affirmed, leaving the unaddressed ineffective-assistance issues to possible consideration on collateral review under 28 U.S.C. § 2255. Subsequently, the Supreme Court held in Ruan v. United States, 142 S. Ct. 2370 (2022), that “once a defendant meets the burden of producing evidence that his or her conduct was ‘authorized’” under § 841(a), “the Government must prove beyond a reasonable doubt that the defendant knowingly or intentionally acted in an unauthorized manner.”

Id. at 2376. Sakkal timely petitioned for certiorari, contending that in light of Ruan the district court erred in its jury instructions on the mens rea requirement under § 841(a). The United States advised the Court to grant certiorari, vacate the decision below, and remand the case for further consideration (GVR) in light of Ruan. The Supreme Court did just that. The fact that the United States endorsed the GVR did not waive its argument that Sakkal failed to preserve the Ruan issue in the district court, so we apply plain error review. Because the instructions below survive deferential plain-error review, we adhere to our prior judgment of affirmance. This, however, does not preclude Sakkal from raising the Ruan issue as part of his ineffective-assistance-of-counsel claims in a subsequent collateral attack under 28 U.S.C. § 2255.

Saad Sakkal practiced medicine at Lindenwald Medical Association from February 2015 to December 2016. Sakkal was licensed to practice medicine in Ohio and also had a Drug Enforcement Administration (DEA) registration number to dispense Schedule II through Schedule V controlled substances. The DEA began investigating Sakkal’s prescription practices after a referral from the Ohio Medical Board, which had received several phone calls from pharmacists about Sakkal’s issuance of problematic prescriptions.

In June 2018, a grand jury returned a thirty-nine-count indictment against Sakkal: thirty counts of illegal distribution of a controlled substance in violation of 21 U.S.C. § 841(a)(1); two counts of distribution of a controlled substance that resulted in death in violation of 21 U.S.C. § 841(b)(1)(C); and seven counts of using the registration number of another to dispense a controlled substance in violation of 21 U.S.C. § 843(a)(2).

At trial, the Government introduced testimony that Sakkal utilized several dangerous prescription methods. The Government’s expert, Dr. Timothy King, testified that Sakkal was prescribing multiple substances that served the same purpose and that this “therapeutic

duplication” risked “significant adverse effects, including respiratory sedation and death.” Sakkal also prescribed several dangerous combinations of controlled substances, including: (1) amphetamines and opioids; (2) methadone with a benzodiazepine and an amphetamine; and (3) opioids with a benzodiazepine and a muscle relaxant, Soma. Finally, Sakkal sometimes prescribed high amounts of controlled substances.

The Government also presented testimony that Sakkal ignored warning signs about the danger of his prescription practices. Employees at Lindenwald administered drug screens to determine if patients were taking their controlled substances as prescribed and to evaluate whether the patient was also taking illegal controlled substances. These drug screens operate as an objective method to ensure that controlled-substance prescriptions do not contribute to a risk of overdose or maintenance of an addiction. Sakkal’s records indicated that his patients’ drug screens sometimes revealed that patients were taking unprescribed controlled substances or were not taking prescribed controlled substances. Sakkal’s records never showed that he discharged or disciplined a patient because of the concerning drug screens.

Sakkal also failed to use the Ohio Automated Rx Reporting System (OARRS) to monitor his patients’ prescriptions for controlled substances. This system is designed to log all of a patient’s controlled-substance prescriptions that are filled or dispensed in Ohio. This allows a physician to ensure that patients have not already received a prescription for their ailments and to confirm that patients have not been doctor shopping to obtain controlled substances. Even when other Lindenwald employees provided Sakkal with OARRS reports for his patients, he did not review the reports.

Several pharmacies became aware of Sakkal’s prescription practices and began calling Lindenwald to discuss concerns about them. Sakkal met with at least three pharmacies to discuss

these concerns, but he did not change his prescribing practices. Some pharmacies decided to stop filling Sakkal’s prescriptions for controlled substances. In addition to charging Sakkal with illegal distribution of controlled substances, the indictment charged Sakkal with two counts of illegally distributing controlled substances that resulted in a patient’s death.

At trial Sakkal requested inclusion of jury instructions regarding the “except as authorized”

provision of 21 U.S.C. § 841(a). As relevant here, Sakkal proposed (instruction no. 3) instructing the jury that the Government must prove he “acted with intent to distribute the drugs and with intent to distribute them outside the course of professional practice,” and that, to find him guilty, “the jury must make a finding of intent, not merely with respect to distribution, but also with respect to [Sakkal’s] intent to act as a pusher rather than a medical professional.” He further requested the court include an instruction stating that a physician does not violate § 841 if he prescribed the substances in “good faith” in “accordance with what the physician should reasonably believe to be a proper medical practice.” Sakkal also requested the court instruct the jury as to the meaning of “outside the bounds of professional medical practice.” According to Sakkal’s proposed instruction no. 2, prescribing outside the bounds of professional medical practice means “prescrib[ing] drugs as being used not for treatment of a patient, but for the purpose of assisting another in the maintenance of a drug habit or of dispensing controlled substances for other than a legitimate medical purpose; for example, the personal profit of the physician.” The district court declined to use Sakkal’s requested instruction on subjective intent (instruction no. 3) but did use his requested instruction on deliberate ignorance and good faith (instruction no. 7). Sakkal made no objection, at either the pre-trial conference or the follow-up conference held after the defense had rested, to the district court’s decisions to use instruction no. 7 and not use instruction no. 3. His only objection to the mens rea section of the jury instructions was to delete

“or was beyond the bounds of medical practice” after “in the usual course of his professional practice,” which the district court did. Thus, with respect to mens rea, the district court instructed as follows:

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Saad Sakkal, (6th Cir. 2023).

United States v. Saad Sakkal (United States v. Saad Sakkal) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Moore v. United States
429 U.S. 20 (Supreme Court, 1976)
Stevens v. Department of Treasury
500 U.S. 1 (Supreme Court, 1991)
United States v. Olano
507 U.S. 725 (Supreme Court, 1993)
Lawrence Ex Rel. Lawrence v. Chater
516 U.S. 163 (Supreme Court, 1996)
Lee v. Kemna
534 U.S. 362 (Supreme Court, 2002)
United States v. Williams
612 F.3d 500 (Sixth Circuit, 2010)
United States v. Fayez Damra
621 F.3d 474 (Sixth Circuit, 2010)
United States v. Gibbs
626 F.3d 344 (Sixth Circuit, 2010)
United States v. Lorne Semrau
693 F.3d 510 (Sixth Circuit, 2012)
Greer v. United States
593 U.S. 503 (Supreme Court, 2021)
Xiulu Ruan v. United States
597 U.S. 450 (Supreme Court, 2022)
Salgado v. United States
140 S. Ct. 2640 (Supreme Court, 2020)